Showing 2981-2990 of 3039 results for "".
- Lenstec Completes Enrollment of FDA Trial for SBL-3 IOLhttps://modernod.com/news/lenstec-completes-enrollment-of-fda-trial-for-sbl-3-iol/2479919/Lenstec announced that it has completed enrollment of the FDA trial for the SBL-3 IOL. The Lenstec SBL-3 IOL (segmented bifocal lens) is a non-concentric asymmetric multifocal refractive IOL that provides patients with superior near, intermediate, and distance vision. It also improves contrast se
- CDC Launches the Nation’s First Vision and Eye Health Surveillance Systemhttps://modernod.com/news/cdc-launches-the-nations-first-vision-and-eye-health-surveillance-system/2479924/The Centers for Disease Control and Prevention (CDC) has developed the nation’s first Vision and Eye Health Surveillance System (VEHSS). Launched in collaboration with the National Opinion Research Center (NORC), the VEHSS is designed to help health care professionals, researchers, policymakers,
- Roche’s Genentech Unit to Cut 223 Jobs in UShttps://modernod.com/news/roches-genentech-unit-to-cut-223-jobs-in-us/2479930/Roche’s Genentech unit plans to cut 223 jobs from its South San Francisco, California headquarters by the end of the year. The company, which disclosed the staff reductions in a Worker Adjustment and Retraining Notification (WARN) posted by the State of California’s Employment Develop
- Nicox Initiates Phase 2 Study of NCX 470 in Open-Angle Glaucoma and Ocular Hypertensionhttps://modernod.com/news/nicox-initiates-phase-2-study-of-ncx-470-in-open-angle-glaucoma-and-ocular-hypertension/2479962/Nicox announced the initiation of a phase 2 clinical study evaluating NCX 470, its novel, second-generation nitric oxide (NO)-donating prostaglandin analog, for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension by enrolling 10 patient
- EyePoint Pharmaceuticals Announces Presentation of Data Highlighting Yutiq for Posterior Segment Uveitishttps://modernod.com/news/eyepoint-pharmaceuticals-announces-presentation-of-data-highlighting-yutiq-for-posterior-segment-uveitis/2479984/EyePoint Pharmaceuticals announced the presentation of 12-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for noninfectious posterior segment uveitis. The data were presented at the American Society of R
- Genentech Unveils New Clinical Data For the First Eye Implant for Wet AMDhttps://modernod.com/news/genentech-unveils-positive-phase-2-results-for-the-first-eye-implant-for-wet-amd/2479987/Genentech announced positive topline results from the phase 2 LADDER study evaluating the efficacy and safety of its investigational Port Delivery System (PDS) with ranibizumab in people with wet age-related macular degeneration (AMD). The small, refillable eye implant, which is slightly l
- Apellis Pharmaceuticals’ APL-2 Receives FDA Fast Track Designation for the Treatment of Patients with GAhttps://modernod.com/news/apellis-pharmaceuticals-apl-2-receives-fast-track-designation-from-fda-for-the-treatment-of-patients-with-geographic-atrophy/2479993/Apellis Pharmaceuticals announced that the FDA has granted fast track designation to the company’s APL-2, a novel inhibitor of complement factor C3 as a next generation monotherapy, for the treatment of patients with geographic atrophy (GA). The FDA’s fast track program faci
- U.S. Court Rejects Allergan Bid to Shield Patents Through Tribe Dealhttps://modernod.com/news/u-s-court-rejects-allergan-bid-to-shield-patents-through-tribe-deal/2480000/A U.S. appeals court on Friday rejected a novel strategy adopted by drug company Allergan to shield patents from review by an administrative court by transferring them to a Native American tribe, according to a
- Alcon Introduces Ngenuity 3D Visualization System with Datafusion Vitreoretinal Surgery Devicehttps://modernod.com/news/alcon-introduces-ngenuity-3d-visualization-system-with-datafusion-vitreoretinal-surgery-device/2480001/Alcon launched the new Ngenuity 3D Visualization System with Datafusion at the 2018 American Society of Retina Specialists (ASRS) annual meeting. With the addition of the Datafusion software, Ngenuity now also offers integration with the Constellation Vision System for vitreoretinal surgery. The
- Allergan and Molecular Partners Announce Positive Phase 3 Clinical Trials for Abicipar Pegol for the Treatment of Wet AMDhttps://modernod.com/news/allergan-and-molecular-partners-announce-positive-phase-3-clinical-trials-for-abicipar-pegol-for-the-treatment-of-wet-amd/2480008/Allergan and Molecular Partners announced the release of two positive clinical trials, SEQUOIA and CEDAR, for abicipar, demonstrating that both the 8-week and 12-week treatment regimens met the prespecified primary endpoint of noninferiority to ranibizumab. SEQUOIA and CEDAR are identical